Cancer-Associated Thrombosis and Beyond: Biomarkers, Treatments, and Cancer-Hemostasis Interactions

Gyldenholm, Tua; Larsen, Julie Brogaard

doi:10.1055/s-0043-1778104

Cited by 1 publication

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other not so common appearances of VTE include superficial vein thrombosis, catheter-related thrombosis, and thrombi in unusual sites in the body [ 11 ]. In addition to the potentially fatal complications of thromboembolism (TE) events, cancer patients also report that thromboembolic events have a significant negative influence on overall quality of life [ 12 ]. Overall, the degree of cancer progression plays a key role in the risk of developing VTE [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Pancreatic Cancer and Venous Thromboembolism

Prouse,

Mohammad,

Ghosh

et al. 2024

IJMS

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic cancers and is the most fatal of all cancers. The treatment response from combination chemotherapies is far from satisfactory and surgery remains the mainstay of curative strategies. These challenges warrant identifying effective treatments for combating this deadly cancer. PDAC tumor progression is associated with the robust activation of the coagulation system. Notably, cancer-associated thrombosis (CAT) is a significant risk factor in PDAC. CAT is a concept whereby cancer cells promote thromboembolism, primarily venous thromboembolism (VTE). Of all cancer types, PDAC is associated with the highest risk of developing VTE. Hypoxia in a PDAC tumor microenvironment also elevates thrombotic risk. Direct oral anticoagulants (DOACs) or low-molecular-weight heparin (LMWH) are used only as thromboprophylaxis in PDAC. However, a precision medicine approach is recommended to determine the precise dose and duration of thromboprophylaxis in clinical setting.

show abstract

Section: Introductionmentioning

confidence: 99%